Clinical development failure
Pipeline assets are early stage and depend on positive trial results to support NDA filings and approvals.
- Scope
- LPCN 1154, LPCN 2201, LPCN 2101, LPCN 1148, LPCN 2401, LPCN 1107
- Materiality
- high
Lipocine Inc.
Lipocine Inc. is a U.S.-based biopharmaceutical company developing oral drug-delivery products built on a proprietary lipid-based technology platform. Its programs target hard-to-deliver molecules across testosterone replacement, CNS disorders, liver disease, and women’s health, with TLANDO as its approved commercial product and the rest of the pipeline still in development.
−521,6 %
−487,1 %
−82,3 %
6.68
6.68
| % | |
|---|---|
| Commercial product | 25% Approved oral testosterone replacement therapy marketed through license partners. |
| CNS pipeline | 35% Oral neuroactive steroid candidates for postpartum depression, MDD, and epilepsy. |
| Liver disease pipeline | 15% Programs aimed at decompensated cirrhosis and prevention of overt hepatic encephalopathy. |
| Women’s health pipeline | 15% Development assets focused on postpartum depression and pre-term birth. |
| Licensing and collaboration revenue | 10% Upfront, milestone, royalty, and research-support income from partners. |
Lipocine sells primarily through licensing and commercialization partners rather than direct hospital or retail...
- Territory license partnersprimary
Verity, SPC, Pharmalink, and Aché commercialize TLANDO in their territories and pay milestones/royalties.
- Prescribing physiciansprimary
Endocrinology, urology, psychiatry, neurology, and hepatology prescribers choose oral options for patients.
- Patientsprimary
Men and women seeking oral therapies that may improve convenience, adherence, and tolerability.
- Development partnerssecondary
Potential collaborators for LPCN 1148, LPCN 2401, LPCN 1107, LPCN 1154, LPCN 2201, and LPCN 2101.
- Service providerssecondary
CROs and contract manufacturers that support clinical trials and drug production.
Lipocine is headquartered and primarily operated from Salt Lake City, Utah, with most employees based there...
- •Headquarters and main operations in Salt Lake City, Utah
- •Most employees work from the Salt Lake City facility
- •Revenue comes mainly from partner territories via licensing and royalties
- •No direct product sales yet; commercialization depends on approvals
- •Future expansion outside current territories is a strategic option
Lipocine’s strategy is to use its oral drug-delivery platform to create differentiated products for large unmet medical...
01
Support TLANDO partner commercializationshort-term
Royalty and milestone income depends on partner execution and market uptake.
02
Advance CNS pipeline candidatesmedium-term
These programs could create future value if clinical data and regulatory progress are positive.
03
Pursue partnerships for non-core assetsmedium-term
Partnerships reduce funding burden and broaden development reach.
04
Maintain IP and operating flexibilityshort-term
Patent protection and lean overhead are critical for a small development-stage biotech.
Lipocine remains a development-stage biotech with heavy dependence on clinical outcomes, FDA review, and partner...
Regulatory approval risk
The company may not receive FDA approval or approval outside the U.S. for product candidates.
- Scope
- All pipeline programs and future geographic expansion
- Materiality
- high
Partner commercialization risk
TLANDO revenue depends on third-party licensees successfully marketing and distributing the product.
- Scope
- Verity, SPC, Pharmalink, Aché territories
- Materiality
- high
Financing risk
The company expects to need additional capital through equity, debt, or partnering.
- Scope
- Operating runway and clinical development budget
- Materiality
- high
Third-party dependence
CROs and contract manufacturers perform substantial trial and manufacturing work.
- Scope
- Clinical timelines, supply continuity, quality control
- Materiality
- medium
Revenue recognition under partner agreements
Affects reported revenue timing and comparability
Royalty revenue from TLANDO sales
Creates quarter-to-quarter revenue volatility
R&D expense estimation
Can change operating loss and cash burn
Lease accounting
Affects operating expense and balance sheet liabilities
: 28.4.2026